FLIR will focus on visible cameras, thermal cameras, and radar systems for use in challenging environmental conditions and ...

FLIR will highlight its industry-leading security and safety solutions at Intersec 2025 (Dubai World Trade Centre, 14-16 ...

Eylea HD is a high-dose version of Eylea. Regeneron’s phase III QUASAR study evaluated the efficacy and safety of Eylea HD in patients with RVO compared with the current standard of care ...

Regeneron (REGN) Pharmaceuticals announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD Injection 8 mg for the treatment of patients with macular edema following ...

The study found that approximately 90% of patients treated with EYLEA HD maintained 8-week dosing intervals through 36 weeks. The QUASAR trial was a global, double-masked, active-controlled study ...

Regeneron's EYLEA HD met the primary endpoint in the Phase 3 QUASAR trial for macular edema following retinal vein occlusion. Vision gains with EYLEA HD every 8 weeks matched the current standard ...

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or aflibercept injection 8 mg for the treatment of patients ...

FLIR will highlight its pioneering security and safety solutions at Intersec 2025 (Dubai World Trade Centre, 14-16 January), ...

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and ...